Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Scorpio2on May 04, 2019 1:04pm
131 Views
Post# 29710859

RE:RE:RE:RE:RE:I am hoping the company maximizes this AUA event

RE:RE:RE:RE:RE:I am hoping the company maximizes this AUA event This is strange. The original presentation relating to the Phase 1 b clinical trial by Lothar Lilge, Angelica Manalac, Leonid Vesselov, Wayne Embree, Arkady Mandel, Naughan Betz, Michael Jewett and Girish Kulkani was replaced by a different presentation on Bladder Cancer: Non Invasive II with session moderators: Mark S. Soloway, Boris Gershman and Paul David Anderson.

If you go to the original presentation details though, it clearly states: Source of Funding: Theralase Technologies and the Government of Ontario.

Either presenters had to back out of this prestigious presentation or maybe there is an issue with the disclosure that the Govmt of Ontario has been (or possibly continues to be) involved in funding. 

All sounds a bit mysterious.  
Bullboard Posts